

# 340B Program Operations Certificate Practice Exam (Sample)

## Study Guide



**Everything you need from our exam experts!**

**Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.**

**ALL RIGHTS RESERVED.**

**No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.**

**Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.**

**SAMPLE**

# Table of Contents

<b>Copyright</b> .....	<b>1</b>
<b>Table of Contents</b> .....	<b>2</b>
<b>Introduction</b> .....	<b>3</b>
<b>How to Use This Guide</b> .....	<b>4</b>
<b>Questions</b> .....	<b>5</b>
<b>Answers</b> .....	<b>8</b>
<b>Explanations</b> .....	<b>10</b>
<b>Next Steps</b> .....	<b>16</b>

# Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

**Remember:** successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

# How to Use This Guide

**This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:**

## **1. Start with a Diagnostic Review**

**Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.**

## **2. Study in Short, Focused Sessions**

**Break your study time into manageable blocks (e.g. 30 - 45 minutes). Review a handful of questions, reflect on the explanations.**

## **3. Learn from the Explanations**

**After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.**

## **4. Track Your Progress**

**Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.**

## **5. Simulate the Real Exam**

**Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.**

## **6. Repeat and Review**

**Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.**

**There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!**

## Questions

- 1. What is NOT a patient identification requirement for the 340B program?**
  - A. Proof of residency**
  - B. Insurance verification**
  - C. Social security number documentation**
  - D. Proof of income**
- 2. What type of services does a Community Health Center (CHC) provide related to pregnancy and childbirth?**
  - A. Pediatric Services**
  - B. Obstetrics Services**
  - C. Gynecological Services**
  - D. General Health Services**
- 3. What term describes medications designated for rare diseases or conditions?**
  - A. 340B drugs**
  - B. Orphan drugs**
  - C. Essential medications**
  - D. Specialty drugs**
- 4. What does the 340B program require states to do regarding entity policies?**
  - A. Implement new pricing strategies**
  - B. Address 340B entity policies**
  - C. Enhance reporting measures**
  - D. Support patients financially**
- 5. What pricing model is based on discounted rates achieved through group purchasing agreements?**
  - A. HRSA Pricing**
  - B. GPO Pricing**
  - C. Bundle Pricing**
  - D. Separate Reimbursement**

- 6. What is vital when managing orphan drug status?**
- A. Regular market analysis**
  - B. Collaboration with medical institutions**
  - C. Engagement with the drug manufacturer**
  - D. Assessment of retail pricing**
- 7. Which of the following best describes the role of split-billing software?**
- A. To manage drug administration records**
  - B. To facilitate drug purchases across different accounts**
  - C. To track patient health outcomes**
  - D. To handle billing disputes**
- 8. What is a primary consequence of the CMS rule regarding drug reimbursement for 340B drugs?**
- A. Increased funding for medical research**
  - B. Enhanced patient outcome tracking**
  - C. Reduced reimbursement rates based on drug acquisition costs**
  - D. Broader access to specialty medications**
- 9. How does the 340B Program aim to improve health outcomes for patients?**
- A. By increasing drug costs**
  - B. By providing access to affordable medication**
  - C. By minimizing healthcare provider involvement**
  - D. By centralizing all medication distribution**
- 10. What type of charges cover support for software after purchase?**
- A. Installation fees**
  - B. Maintenance charges**
  - C. Service fees**
  - D. Upgrade costs**



## **Answers**

SAMPLE

1. C
2. B
3. B
4. B
5. B
6. C
7. B
8. C
9. B
10. B

SAMPLE

## **Explanations**

**1. What is NOT a patient identification requirement for the 340B program?**

- A. Proof of residency**
- B. Insurance verification**
- C. Social security number documentation**
- D. Proof of income**

In the context of the 340B program, patient identification is essential for ensuring that discounts on medications are provided to eligible patients. Organizations participating in the 340B program must have processes in place to identify and verify patient eligibility based on specific criteria. The requirement for patient identification emphasizes the need for proof of residency, insurance verification, and proof of income. These elements help ensure that patients are indeed eligible based on the program's guidelines and that they meet the necessary criteria to receive reduced prices on medications. However, documentation of a social security number is not explicitly required by the 340B program for patient identification. While some organizations may choose to collect this information for their own administrative purposes or to support patient identification processes, it is not mandated by the program itself. Therefore, the absence of a requirement to document social security numbers positions this choice as the correct answer regarding what is NOT a requirement for patient identification for the 340B program.

**2. What type of services does a Community Health Center (CHC) provide related to pregnancy and childbirth?**

- A. Pediatric Services**
- B. Obstetrics Services**
- C. Gynecological Services**
- D. General Health Services**

A Community Health Center (CHC) plays a critical role in providing comprehensive healthcare services that are accessible and affordable. When it comes to pregnancy and childbirth, the most relevant services offered by a CHC are obstetrics services. These services specifically focus on the care of pregnant individuals, including prenatal care, labor and delivery support, and postpartum care. Obstetrics encompasses the medical and surgical care related to pregnancy, childbirth, and the postpartum period, making it integral to ensuring the health and safety of both the mother and the baby during this critical time. Community Health Centers are structured to provide these essential services as part of their mission to promote health and meet the needs of underserved populations. While pediatric services do relate to children's health, they address the medical needs of infants and children rather than the specific needs of pregnant individuals. Gynecological services, on the other hand, focus on women's reproductive health outside of the scope of pregnancy, including routine examinations and screenings, and general health services typically cover a wide array of non-specialized healthcare without the focus on obstetrics. Thus, obstetrics services stand out as the correct answer pertaining specifically to pregnancy and childbirth.

**3. What term describes medications designated for rare diseases or conditions?**

- A. 340B drugs
- B. Orphan drugs**
- C. Essential medications
- D. Specialty drugs

The term that describes medications designated for rare diseases or conditions is orphan drugs. These are specifically developed to treat conditions that affect a small percentage of the population, and they may not be financially viable for manufacturers to produce without incentives. The term "orphan" refers to the fact that these drugs are developed for "orphaned" conditions that often lack sufficient market potential for pharmaceutical companies, leading to initiatives that encourage their development, such as federal grants or tax incentives. Orphan drugs are significant in the context of the healthcare system because they address unmet medical needs for patients with rare diseases. Understanding this term is essential for professionals in the healthcare and pharmaceutical fields, especially those involved in drug distribution and access programs like the 340B Program, which aims to enhance patient access to necessary medications, including orphan drugs. In contrast, the other terms listed do not specifically refer to medications for rare diseases. 340B drugs pertain to the pricing and distribution mechanisms in the 340B Drug Pricing Program, essential medications refer to drugs that are considered vital for maintaining health and treating common conditions, and specialty drugs typically refer to high-cost medications that are used to treat complex or chronic diseases, which may not necessarily be for rare conditions.

**4. What does the 340B program require states to do regarding entity policies?**

- A. Implement new pricing strategies
- B. Address 340B entity policies**
- C. Enhance reporting measures
- D. Support patients financially

The 340B Program requires states to ensure that entity policies are addressed in order to maintain compliance with the requirements set forth by the program. This includes ensuring that eligible entities, such as certain hospitals and clinics, have policies that govern their participation in the 340B Program. These policies typically encompass aspects such as the acquisition and use of drugs purchased at reduced prices, the management of patient eligibility, and the reporting of program-related data to ensure transparency and accountability. By addressing these entity policies, states help to safeguard the integrity of the 340B Program, ensuring that the reduced-pricing benefits are used appropriately to support vulnerable populations. This requirement is crucial for the effective operation of the program, as it mandates that covered entities adhere to specific guidelines that promote the program's goals of reducing healthcare costs for eligible patients.

**5. What pricing model is based on discounted rates achieved through group purchasing agreements?**

**A. HRSA Pricing**

**B. GPO Pricing**

**C. Bundle Pricing**

**D. Separate Reimbursement**

The correct choice is based on the notion that group purchasing organizations (GPOs) negotiate pricing with manufacturers, allowing healthcare entities to benefit from discounted rates. GPO pricing utilizes collective buying power from multiple organizations, which can lead to significant cost savings on pharmaceuticals and other medical supplies. In this model, GPOs leverage the volume of purchases across different members to negotiate favorable terms, which are then passed on to member organizations. This is particularly important for healthcare providers that rely heavily on medications and other supplies, as it can substantially impact their operating costs and ultimately improve access to essential drugs for patients. Other options, while relevant in the context of pricing and reimbursement strategies, do not specifically represent the pricing model derived from group purchasing agreements. For example, HRSA pricing pertains to the prices established under the Health Resources and Services Administration for eligible entities, and bundle pricing relates to fixed pricing for a set of services or products rather than negotiated discounts based on collective purchasing. Separate reimbursement refers to reimbursement strategies for individual items outside of collaborative agreements, which would not involve group purchasing dynamics.

**6. What is vital when managing orphan drug status?**

**A. Regular market analysis**

**B. Collaboration with medical institutions**

**C. Engagement with the drug manufacturer**

**D. Assessment of retail pricing**

Engagement with the drug manufacturer is crucial when managing orphan drug status because it allows for direct communication about drug development, regulatory requirements, and marketing strategies specific to orphan drugs. Manufacturers of orphan drugs must navigate unique challenges, including the limited patient population, specific regulatory incentives, and potential market exclusivity. By engaging with the manufacturer, stakeholders can ensure that they are aligned in their objectives for drug accessibility, comply with the regulations surrounding orphan drugs, and address any manufacturing or distribution issues that may arise. Additionally, this engagement can lead to insights into ongoing research and development that could affect the drug's status and availability in the market. While regular market analysis, collaboration with medical institutions, and assessment of retail pricing are important components of pharmaceutical management, they do not specifically address the unique aspects and regulatory considerations related to managing orphan drug status. Understanding the specifics of the drug's development process and maintaining a strong relationship with the manufacturer is essential for navigating the complexities of the orphan drug landscape effectively.

**7. Which of the following best describes the role of split-billing software?**

- A. To manage drug administration records**
- B. To facilitate drug purchases across different accounts**
- C. To track patient health outcomes**
- D. To handle billing disputes**

The role of split-billing software is primarily designed to facilitate drug purchases across different accounts, making choice B the correct option. This type of software is specifically utilized in healthcare settings, particularly by entities participating in the 340B program, to ensure that medications are billed accurately based on the appropriate pricing tiers for different groups or accounts. In practice, split-billing software allows healthcare providers to categorize and manage inventory and billing for the medications they dispense, ensuring that 340B eligible drugs are billed at the necessary reduced prices while other purchases remain at standard pricing. Notably, this capability is essential for maintaining compliance with the program's regulations and structure, as it helps organizations navigate the complexities of their purchasing and inventory management processes. The other options, while significant in healthcare operations, do not directly pertain to the specific function of split-billing software. Managing drug administration records involves tracking how medications are given to patients; tracking patient health outcomes focuses on collecting data related to treatment effectiveness; and handling billing disputes deals with resolving discrepancies in billed amounts. All these are separate functions that do not encapsulate the core role of split-billing software in the context of managing drug purchases effectively across different financial accounts.

**8. What is a primary consequence of the CMS rule regarding drug reimbursement for 340B drugs?**

- A. Increased funding for medical research**
- B. Enhanced patient outcome tracking**
- C. Reduced reimbursement rates based on drug acquisition costs**
- D. Broader access to specialty medications**

The choice highlighting reduced reimbursement rates based on drug acquisition costs is correct because it reflects a significant outcome of the Centers for Medicare & Medicaid Services (CMS) rule concerning the reimbursement framework for 340B drugs. Under this rule, CMS has adjusted the reimbursement rates for drugs acquired under the 340B program, aiming to align payments more closely with the actual acquisition costs of these drugs. This change is designed to ensure that the financial benefits of the 340B discounts primarily support the safety-net providers the program serves. By reducing reimbursement rates, the intention is to mitigate potential profit margins that could arise from the program, further ensuring resources are directed toward patient care and supporting health care organizations that treat low-income communities. Such policies can financially impact healthcare providers by potentially lowering their revenue from 340B drugs, which has broader implications for the sustainability of the services they offer, particularly in underserved areas. Other options relate to aspects that do not have a direct correlation with the CMS rule on drug reimbursement. For instance, increased funding for medical research may not be influenced by this specific CMS rule and thus does not capture the key consequence. Similarly, enhanced patient outcome tracking and broader access to specialty medications are not directly tied to the reimbursement rates or the overarching goals of the CMS.

**9. How does the 340B Program aim to improve health outcomes for patients?**

- A. By increasing drug costs
- B. By providing access to affordable medication**
- C. By minimizing healthcare provider involvement
- D. By centralizing all medication distribution

The 340B Program is designed specifically to improve health outcomes for patients by providing access to affordable medication. This program allows eligible healthcare providers, including safety-net hospitals and clinics, to purchase outpatient drugs at significantly reduced prices. As a result, these providers can offer medications to underserved populations at little to no cost, which is crucial for those who might otherwise struggle to afford necessary treatments. By making medications more accessible, the 340B Program helps patients adhere to their prescribed treatment regimens, leading to better management of chronic diseases and overall improved health outcomes. The financial savings from the discounted drugs can also be reinvested into patient care services, further enhancing healthcare access and quality for vulnerable populations. The other options focus on aspects that do not align with the program's goals. Increasing drug costs and minimizing healthcare provider involvement run contrary to the objectives of improving access and optimizing patient care. Centralizing medication distribution does not address the immediate need for affordability and access that the 340B Program seeks to fulfill. Therefore, the focus on affordable medications is what fundamentally supports better health outcomes for patients.

**10. What type of charges cover support for software after purchase?**

- A. Installation fees
- B. Maintenance charges**
- C. Service fees
- D. Upgrade costs

Maintenance charges refer to the costs associated with the ongoing support and upkeep of software after its initial purchase. This usually includes services such as troubleshooting, updates, bug fixes, and technical support, ensuring the software continues to operate effectively over time. These charges are crucial for users who rely on software for critical operations, as they help maintain its functionality and can enhance security by keeping the software updated against vulnerabilities. In contrast, installation fees typically cover the costs related to setting up the software for the first time, while service fees may refer to general support services that aren't specifically designated for ongoing software maintenance. Upgrade costs, on the other hand, are tied to improvements or new versions of the software, not the continual support necessary after the initial purchase. Thus, maintenance charges are the key to sustained software functionality post-purchase.



## Next Steps

**Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.**

**As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.**

**If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at [hello@examzify.com](mailto:hello@examzify.com).**

**Or visit your dedicated course page for more study tools and resources:**

**<https://340bprogramoperations.examzify.com>**

**We wish you the very best on your exam journey. You've got this!**